us-court-of-appeals-for-the-federal-circuit-1-

Heidi Besen / Shutterstock

23 January 2024AmericasMarisa Woutersen

Federal Circuit rejects Cellect rehearing on double patenting

En banc petition concerning obviousness-type double-patenting rejected by the Court of Appeals | Decision on patent term adjustment has been closely followed by pharma companies, NYIPLA, and AIPLA.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages